Harrison L I, Gibaldi M
J Pharm Sci. 1977 Aug;66(8):1138-42. doi: 10.1002/jps.2600660822.
A plasma flow rate-limited pharmacokinetic model was developed to describe the distribution of digoxin to the heart, liver, kidneys, skeletal muscle, and GI tract in the rat. The model also provides for renal, hepatic (metabolic and biliary), and GI clearance as well as for biliary and GI secretion and GI reabsorption of digoxin. Predicted concentrations of digoxin in the heart, liver, skeletal muscle, and plasma were consistent with experimental observations in conscious rats after an intravenous dose. The model was extended to describe digoxin concentrations in the plasma of bile duct-ligated rats and ureter-ligated rats, simply by modifying appropriate clearance parameters. Excellent agreement was obtained between predicted and observed urinary excretion rates of digoxin for 12 hr after in intravenous dose to normal and bile duct-ligated rats.
建立了一个血浆流速限制的药代动力学模型,以描述地高辛在大鼠心脏、肝脏、肾脏、骨骼肌和胃肠道中的分布。该模型还考虑了地高辛的肾脏清除、肝脏清除(代谢和胆汁清除)以及胃肠道清除,以及胆汁和胃肠道分泌及胃肠道重吸收。静脉给药后,预测的地高辛在心脏、肝脏、骨骼肌和血浆中的浓度与清醒大鼠的实验观察结果一致。通过简单修改适当的清除参数,该模型被扩展用于描述胆管结扎大鼠和输尿管结扎大鼠血浆中的地高辛浓度。静脉注射给药后,正常大鼠和胆管结扎大鼠12小时内地高辛的预测尿排泄率与观察值之间取得了极好的一致性。